Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease

被引:25
作者
Cancela e Penna, Francisco Guilherme [1 ]
Rosa, Rodrigo Macedo [1 ]
Sales da Cunha, Pedro Ferrari [2 ]
Silva de Souza, Stella Cristina [2 ]
de Abreu Ferrari, Maria de Lourdes [3 ]
机构
[1] Univ Fed Minas Gerais, Hosp Clin, Inst Alfa Gastroenterol, Ave Prof Alfredo Balena 110,Second Floor, BR-30130100 Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Fac Med, Ave Prof Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Ave Prof Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil
关键词
Faecal calprotectin; Crohn's disease; Simple endoscopic score for Crohn's disease; SES-CD; C-reactive protein; INFLAMMATORY-BOWEL-DISEASE; EVIDENCE-BASED CONSENSUS; C-REACTIVE PROTEIN; ACTIVITY SCORE; MANAGEMENT; LACTOFERRIN; DIAGNOSIS; METAANALYSIS; OUTCOMES; UTILITY;
D O I
10.1186/s12876-020-1183-x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Effective control of the inflammatory process in Crohn's disease (CD) is reflected in intestinal mucosal healing. The performances of faecal calprotectin (fcal), clinical and serologic parameters in the inflammatory activity evaluation and their correlation to the simple endoscopic score (SES-CD) are the goals of this study. Methods Patients with CD referred for ileocolonoscopy were prospectively included and distributed according to the degree of endoscopic inflammatory activity into remission, mild activity, and moderate to severe activity groups. The different degrees of endoscopic activity were correlated with the following indexes: Crohn's disease activity index (CDAI), fCal, serum C-reactive protein (CRP), and haemogram. The control group comprised individuals without known intestinal disease who were referred for colorectal cancer screening. Results Eighty colonoscopies were performed in patients with CD and 21 in the control group. The control group had a lower median fCal (59.7 mcg/g) than patients with CD (683 mcg/g, p < 0.001). A moderate Spearman correlation occurred between SES-CD and CRP (r = 0.525), fCal (r = 0.450), and CDAI (r = 0.407), while a weak correlation was found with the platelet count (r = 0.257). Only fCal distinguished patients in remission from those with mild activity (236.6 mcg/g x 654.9 mcg/g, p = 0.014) or moderate to severe activity (236.6 mcg/g x 1128 mcg/g, p < 0.001). An fCal cut-off of 155 mcg/g was sensitive (96%) and accurate (78%) for the diagnosis of endoscopic activity. Conclusions fCal provides greater diagnostic accuracy than the other activity markers for endoscopic activity of patients with CD, moderate correlation to SES-CD, and a capacity to discriminate patients in remission from those with mild or moderate to severe activity.
引用
收藏
页数:10
相关论文
共 44 条
[1]   Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring [J].
Benitez, Jose-Manuel ;
Meuwis, Marie-Alice ;
Reenaers, Catherine ;
Van Kemseke, Catherine ;
Meunier, Paul ;
Louis, Edouard .
GUT, 2013, 62 (12) :1806-1816
[2]   Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease [J].
Bouguen, Guillaume ;
Levesque, Barrett G. ;
Feagan, Brian G. ;
Kavanaugh, Arthur ;
Peyrin-Biroulet, Laurent ;
Colombel, Jean-Frederic ;
Hanauer, Stephen B. ;
Sandborn, William J. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (06) :1042-+
[3]   Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders [J].
Caviglia, Gian Paolo ;
Pantaleoni, Stefano ;
Touscoz, Giovanni Antonio ;
Adriani, Alessandro ;
Rosso, Chiara ;
Smedile, Antonina ;
Pellicano, Rinaldo ;
Astegiano, Marco ;
Bresso, Francesca .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2014, 49 (12) :1419-1424
[4]   Disease monitoring in inflammatory bowel disease [J].
Chang, Shannon ;
Malter, Lisa ;
Hudesman, David .
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (40) :11246-11259
[5]   Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial [J].
Colombel, Jean-Frederic ;
Panaccione, Remo ;
Bossuyt, Peter ;
Lukas, Milan ;
Baert, Filip ;
Vanasek, Tomas ;
Danalioglu, Ahmet ;
Novacek, Gottfried ;
Armuzzi, Alessandro ;
Hebuterne, Xavier ;
Travis, Simon ;
Danese, Silvio ;
Reinisch, Walter ;
Sandborn, William J. ;
Rutgeerts, Paul ;
Hommes, Daniel ;
Schreiber, Stefan ;
Neimark, Ezequiel ;
Huang, Bidan ;
Zhou, Qian ;
Mendez, Paloma ;
Petersson, Joel ;
Wallace, Kori ;
Robinson, Anne M. ;
Thakkar, Roopal B. ;
D'Haens, Geert .
LANCET, 2017, 390 (10114) :2779-2789
[6]   Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases [J].
Colombel, Jean-Frederic ;
Narula, Neeraj ;
Peyrin-Biroulet, Laurent .
GASTROENTEROLOGY, 2017, 152 (02) :351-+
[7]   Measuring disease activity in Crohn's disease: what is currently available to the clinician [J].
D'Inca, Renata ;
Caccaro, Roberta .
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 :151-161
[8]  
KOTZE Lorete Maria da Silva, 2015, Arq. Gastroenterol., V52, P50, DOI 10.1590/S0004-28032015000100011
[9]   Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD [J].
Daperno, M ;
D'Haens, G ;
Van Assche, G ;
Baert, F ;
Bulois, P ;
Maunoury, V ;
Sostegni, R ;
Rocca, R ;
Pera, A ;
Gevers, A ;
Mary, JY ;
Colombel, JF ;
Rutgeerts, P .
GASTROINTESTINAL ENDOSCOPY, 2004, 60 (04) :505-512
[10]   Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature [J].
Umar Darr ;
Nabeel Khan .
Current Treatment Options in Gastroenterology, 2017, 15 (1) :116-125